PCIDB

KNApSAcK Metabolite C00043440

Metabolite

KNApSAcK Entry

id C00043440
Name Daunomycin / Rubomycin C
CAS RN 20830-81-3
Standard InChI InChI=1S/C27H29NO10/c1-10-22(30)14(28)7-17(37-10)38-16-9-27(35,11(2)29)8-13-19(16)26(34)21-20(24(13)32)23(31)12-5-4-6-15(36-3)18(12)25(21)33/h4-6,10,14,16-17,22,30,32,34-35H,7-9,28H2,1-3H3/t10-,14-,16-,17-,22+,27-/m0/s1
Standard InChI (Main Layer) InChI=1S/C27H29NO10/c1-10-22(30)14(28)7-17(37-10)38-16-9-27(35,11(2)29)8-13-19(16)26(34)21-20(24(13)32)23(31)12-5-4-6-15(36-3)18(12)25(21)33/h4-6,10,14,16-17,22,30,32,34-35H,7-9,28H2,1-3H3

Cluster

Phytochemical cluster
KCF-S cluster No. 397

Link

ChEMBL

By standard InChI CHEMBL178
By standard InChI Main Layer CHEMBL9659 CHEMBL178 CHEMBL1197788 CHEMBL1525753 CHEMBL1617377

KEGG

By LinkDB C01907

CTD

By CAS RN D003630

Species

Summary

Plant class

class name count

Family

family name count
Streptomycetaceae 1

List (1)

* NCBI
KNApSAcK organism *ID *family *plant class *kingdom
Streptomyces sp. MST77755 1883 Streptomycetaceae Bacteria

Human Protein / Gene in interaction

136 ChEMBL Protein in interactions

accession description class description compound assay ID (# of activities) # of diseases
(OMIM / KEGG)
P14550 Alcohol dehydrogenase [NADP(+)] Enzyme CHEMBL178 CHEMBL2184160 (1) CHEMBL2184165 (1)
0 / 0
P10635 Cytochrome P450 2D6 Cytochrome P450 2D6 CHEMBL178 CHEMBL1525753 CHEMBL1741321 (2) CHEMBL1909136 (2)
1 / 0
P33527 Multidrug resistance-associated protein 1 drugs CHEMBL178 CHEMBL2077585 (1) CHEMBL2077586 (1)
CHEMBL2076530 (1) CHEMBL2075747 (1)
CHEMBL2076198 (1) CHEMBL2078380 (1)
CHEMBL2078574 (1)
0 / 0
P04637 Cellular tumor antigen p53 Transcription Factor CHEMBL178 CHEMBL1613992 (1) CHEMBL1613995 (1)
7 / 44
Q16637 Survival motor neuron protein Unclassified protein CHEMBL1525753 CHEMBL1613842 (1)
4 / 2
Q99700 Ataxin-2 Unclassified protein CHEMBL1525753 CHEMBL2114784 (1)
1 / 1
O95342 Bile salt export pump drug CHEMBL178 CHEMBL2076235 (1)
2 / 1
P21728 D(1A) dopamine receptor Dopamine receptor CHEMBL178 CHEMBL1909139 (2)
0 / 0
P35354 Prostaglandin G/H synthase 2 Oxidoreductase CHEMBL178 CHEMBL1909131 (2)
0 / 3
Q12809 Potassium voltage-gated channel subfamily H member 2 KCNH, Kv10-12.x (Ether-a-go-go) CHEMBL178 CHEMBL1909190 (2)
2 / 2
P08246 Neutrophil elastase S1A CHEMBL178 CHEMBL1909195 (2)
2 / 1
P33765 Adenosine receptor A3 Adenosine receptor CHEMBL178 CHEMBL1909215 (2)
0 / 0
Q16539 Mitogen-activated protein kinase 14 p38 CHEMBL178 CHEMBL1909201 (2)
0 / 0
P49146 Neuropeptide Y receptor type 2 Neuropeptide Y receptor CHEMBL178 CHEMBL1909176 (2)
0 / 0
P29466 Caspase-1 C14 CHEMBL178 CHEMBL1909193 (2)
0 / 0
P17252 Protein kinase C alpha type Alpha CHEMBL178 CHEMBL1909198 (2)
0 / 0
P27361 Mitogen-activated protein kinase 3 Erk CHEMBL178 CHEMBL1909199 (2)
0 / 0
P14780 Matrix metalloproteinase-9 M10A CHEMBL178 CHEMBL1909197 (2)
2 / 2
Q13547 Histone deacetylase 1 Hydrolase CHEMBL178 CHEMBL2025278 (1) CHEMBL2025279 (1)
0 / 0
O75604 Ubiquitin carboxyl-terminal hydrolase 2 Enzyme CHEMBL1525753 CHEMBL1614331 (1)
0 / 0
P10828 Thyroid hormone receptor beta NR1A2 CHEMBL178 CHEMBL1525753 CHEMBL1614554 (3) CHEMBL1613776 (3)
3 / 1
P00918 Carbonic anhydrase 2 Lyase CHEMBL178 CHEMBL1909123 (2)
1 / 2
P07550 Beta-2 adrenergic receptor Adrenergic receptor CHEMBL178 CHEMBL1909092 (2)
0 / 1
P21397 Amine oxidase [flavin-containing] A Oxidoreductase CHEMBL178 CHEMBL1909169 (2)
1 / 1
P25021 Histamine H2 receptor Histamine receptor CHEMBL178 CHEMBL1909157 (2)
0 / 0
P35367 Histamine H1 receptor Histamine receptor CHEMBL178 CHEMBL1909156 (2)
0 / 0
Q01959 Sodium-dependent dopamine transporter Dopamine CHEMBL178 CHEMBL1909143 (2)
1 / 0
P08912 Muscarinic acetylcholine receptor M5 Acetylcholine receptor CHEMBL178 CHEMBL1909174 (2)
0 / 0
P18825 Alpha-2C adrenergic receptor Adrenergic receptor CHEMBL178 CHEMBL1909090 (2)
0 / 0
P13945 Beta-3 adrenergic receptor Adrenergic receptor CHEMBL178 CHEMBL1909093 (2)
0 / 0
Q9BY41 Histone deacetylase 8 Hydrolase CHEMBL178 CHEMBL2025281 (1)
2 / 0
P08183 Multidrug resistance protein 1 drug CHEMBL178 CHEMBL1908285 (1) CHEMBL1908286 (1)
CHEMBL1908289 (1) CHEMBL1908291 (1)
CHEMBL1908292 (1) CHEMBL2076080 (1)
CHEMBL2076093 (1) CHEMBL2076689 (1)
CHEMBL2076854 (1) CHEMBL2075196 (1)
CHEMBL2076208 (1) CHEMBL2076219 (1)
CHEMBL2076251 (1) CHEMBL2076066 (1)
CHEMBL2078150 (1) CHEMBL2078578 (1)
1 / 0
P25024 C-X-C chemokine receptor type 1 CXC chemokine receptor CHEMBL178 CHEMBL1909127 (2)
0 / 0
P06241 Tyrosine-protein kinase Fyn Src CHEMBL178 CHEMBL1909204 (2)
0 / 0
Q08209 Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform Ser_Thr CHEMBL178 CHEMBL1909202 (2)
0 / 0
P11712 Cytochrome P450 2C9 Cytochrome P450 2C9 CHEMBL178 CHEMBL1525753 CHEMBL1741325 (2) CHEMBL1909135 (2)
0 / 1
P54132 Bloom syndrome protein Enzyme CHEMBL178 CHEMBL1525753 CHEMBL1614117 (2) CHEMBL1614067 (3)
1 / 2
P00533 Epidermal growth factor receptor TK tyrosine-protein kinase EGFR subfamily CHEMBL178 CHEMBL1909203 (2)
1 / 11
P11387 DNA topoisomerase 1 Isomerase CHEMBL178 CHEMBL821429 (1) CHEMBL821436 (1)
CHEMBL814845 (1) CHEMBL1647793 (1)
0 / 0
P11388 DNA topoisomerase 2-alpha Isomerase CHEMBL178 CHEMBL1647795 (1) CHEMBL2025734 (1)
CHEMBL2025753 (1) CHEMBL2025756 (1)
CHEMBL2091136 (1)
0 / 0
P11473 Vitamin D3 receptor NR1I1 CHEMBL178 CHEMBL1794311 (1)
2 / 3
P14416 D(2) dopamine receptor Dopamine receptor CHEMBL178 CHEMBL1909140 (2)
2 / 0
P23219 Prostaglandin G/H synthase 1 Oxidoreductase CHEMBL178 CHEMBL1909130 (2)
0 / 0
P37288 Vasopressin V1a receptor Vasopressin and oxytocin receptor CHEMBL178 CHEMBL1909120 (2)
0 / 0
P41145 Kappa-type opioid receptor Opioid receptor CHEMBL178 CHEMBL1909181 (2)
0 / 0
Q9Y271 Cysteinyl leukotriene receptor 1 Leukotriene receptor CHEMBL178 CHEMBL1909164 (2)
0 / 0
P29274 Adenosine receptor A2a Adenosine receptor CHEMBL178 CHEMBL1909214 (2)
0 / 0
P25929 Neuropeptide Y receptor type 1 Neuropeptide Y receptor CHEMBL178 CHEMBL1909175 (2)
0 / 0
P50052 Type-2 angiotensin II receptor Angiotensin receptor CHEMBL178 CHEMBL1909096 (2)
1 / 1
O15296 Arachidonate 15-lipoxygenase B Enzyme CHEMBL178 CHEMBL1613800 (2)
0 / 0
P17948 Vascular endothelial growth factor receptor 1 Vegfr CHEMBL178 CHEMBL1909118 (2)
0 / 0
P41968 Melanocortin receptor 3 Melanocortin receptor CHEMBL178 CHEMBL1909166 (2)
1 / 0
P00352 Retinal dehydrogenase 1 Enzyme CHEMBL178 CHEMBL1614458 (1)
0 / 0
P11509 Cytochrome P450 2A6 Cytochrome P450 2A6 CHEMBL178 CHEMBL1909133 (2)
0 / 0
Q16665 Hypoxia-inducible factor 1-alpha Transcription Factor CHEMBL1525753 CHEMBL1614456 (1) CHEMBL1613803 (1)
0 / 0
Q92830 Histone acetyltransferase KAT2A Enzyme CHEMBL178 CHEMBL1738606 (1)
0 / 0
P42858 Huntingtin Unclassified protein CHEMBL178 CHEMBL1613918 (1)
1 / 1
P16152 Carbonyl reductase [NADPH] 1 Enzyme CHEMBL178 CHEMBL2184161 (2) CHEMBL2184164 (2)
CHEMBL2184166 (1)
0 / 0
O75496 Geminin Unclassified protein CHEMBL178 CHEMBL2114780 (1)
0 / 0
O60656 UDP-glucuronosyltransferase 1-9 Enzyme CHEMBL178 CHEMBL1908086 (1)
0 / 0
P38398 Breast cancer type 1 susceptibility protein Enzyme CHEMBL178 CHEMBL1525753 CHEMBL1614303 (2)
4 / 2
P04035 3-hydroxy-3-methylglutaryl-coenzyme A reductase Oxidoreductase CHEMBL178 CHEMBL1909158 (2)
0 / 0
P08913 Alpha-2A adrenergic receptor Adrenergic receptor CHEMBL178 CHEMBL1909088 (2)
0 / 0
P21917 D(4) dopamine receptor Dopamine receptor CHEMBL178 CHEMBL1909142 (2)
0 / 0
P30988 Calcitonin receptor Calcitonin receptor CHEMBL178 CHEMBL1909101 (2)
0 / 0
P35462 D(3) dopamine receptor Dopamine receptor CHEMBL178 CHEMBL1909141 (2)
1 / 0
P41143 Delta-type opioid receptor Opioid receptor CHEMBL178 CHEMBL1909180 (2)
0 / 0
Q92731 Estrogen receptor beta NR3A2 CHEMBL178 CHEMBL1909146 (2)
0 / 1
P41595 5-hydroxytryptamine receptor 2B Serotonin receptor CHEMBL178 CHEMBL1909104 (2)
0 / 0
P25101 Endothelin-1 receptor Endothelin receptor CHEMBL178 CHEMBL1909144 (2)
0 / 0
P30411 B2 bradykinin receptor Bradykinin receptor CHEMBL178 CHEMBL1909100 (2)
0 / 0
P32245 Melanocortin receptor 4 Melanocortin receptor CHEMBL178 CHEMBL1909167 (2)
1 / 0
P32238 Cholecystokinin receptor type A Cholecystokinin receptor CHEMBL178 CHEMBL1909129 (2)
0 / 0
P08311 Cathepsin G S1A CHEMBL178 CHEMBL1909194 (2)
0 / 0
Q99720 Sigma non-opioid intracellular receptor 1 Membrane receptor CHEMBL178 CHEMBL1909110 (2)
1 / 0
P03956 Interstitial collagenase M10A CHEMBL178 CHEMBL1909196 (2)
0 / 1
P32241 Vasoactive intestinal polypeptide receptor 1 Vasoactive intestinal peptide receptor CHEMBL178 CHEMBL1909119 (2)
0 / 0
Q03164 Histone-lysine N-methyltransferase 2A Enzyme CHEMBL178 CHEMBL1525753 CHEMBL1614257 (3) CHEMBL1614410 (1)
CHEMBL1614531 (3)
1 / 3
O94782 Ubiquitin carboxyl-terminal hydrolase 1 Enzyme CHEMBL178 CHEMBL1525753 CHEMBL1794467 (3) CHEMBL1794492 (1)
0 / 0
P04150 Glucocorticoid receptor NR3C1 CHEMBL178 CHEMBL1909150 (2)
0 / 1
P08172 Muscarinic acetylcholine receptor M2 Acetylcholine receptor CHEMBL178 CHEMBL1909171 (2)
2 / 0
P11229 Muscarinic acetylcholine receptor M1 Acetylcholine receptor CHEMBL178 CHEMBL1909170 (2)
0 / 0
P21554 Cannabinoid receptor 1 Cannabinoid receptor CHEMBL178 CHEMBL1909122 (2)
0 / 0
P31645 Sodium-dependent serotonin transporter Serotonin CHEMBL178 CHEMBL1909109 (2)
2 / 0
P04626 Receptor tyrosine-protein kinase erbB-2 TK tyrosine-protein kinase EGFR subfamily CHEMBL178 CHEMBL1909205 (2)
5 / 10
P20309 Muscarinic acetylcholine receptor M3 Acetylcholine receptor CHEMBL178 CHEMBL1909172 (2)
1 / 0
P21452 Substance-K receptor Neurokinin receptor CHEMBL178 CHEMBL1909114 (2)
0 / 0
P51679 C-C chemokine receptor type 4 CC chemokine receptor CHEMBL178 CHEMBL1909125 (2)
0 / 0
P51681 C-C chemokine receptor type 5 CC chemokine receptor CHEMBL178 CHEMBL1909126 (2)
3 / 0
P50406 5-hydroxytryptamine receptor 6 Serotonin receptor CHEMBL178 CHEMBL1909108 (2)
0 / 0
P41597 C-C chemokine receptor type 2 CC chemokine receptor CHEMBL178 CHEMBL1909124 (2)
1 / 0
P28482 Mitogen-activated protein kinase 1 Erk CHEMBL178 CHEMBL1613808 (1) CHEMBL1909200 (2)
0 / 0
P08575 Receptor-type tyrosine-protein phosphatase C Enzyme CHEMBL178 CHEMBL1909207 (2)
2 / 1
P05177 Cytochrome P450 1A2 Cytochrome P450 1A2 CHEMBL178 CHEMBL1525753 CHEMBL1741322 (2) CHEMBL1909132 (2)
0 / 0
P08253 72 kDa type IV collagenase M10A CHEMBL178 CHEMBL662786 (1)
1 / 3
Q99714 3-hydroxyacyl-CoA dehydrogenase type-2 Enzyme CHEMBL178 CHEMBL1613910 (1)
3 / 3
Q9UNQ0 ATP-binding cassette sub-family G member 2 ATP binding cassette CHEMBL178 CHEMBL2077081 (1) CHEMBL2077538 (1)
CHEMBL2078553 (1)
2 / 0
Q92887 Canalicular multispecific organic anion transporter 1 Unclassified protein CHEMBL178 CHEMBL2078561 (1)
1 / 1
O76074 cGMP-specific 3',5'-cyclic phosphodiesterase PDE_5A CHEMBL178 CHEMBL1909186 (2)
0 / 0
P03372 Estrogen receptor NR3A1 CHEMBL178 CHEMBL1909145 (2)
1 / 1
P08588 Beta-1 adrenergic receptor Adrenergic receptor CHEMBL178 CHEMBL1909091 (2)
1 / 0
P22303 Acetylcholinesterase Hydrolase CHEMBL178 CHEMBL1909212 (2)
1 / 0
P28223 5-hydroxytryptamine receptor 2A Serotonin receptor CHEMBL178 CHEMBL1909211 (2)
0 / 0
P28335 5-hydroxytryptamine receptor 2C Serotonin receptor CHEMBL178 CHEMBL1909105 (2)
0 / 0
P35372 Mu-type opioid receptor Opioid receptor CHEMBL178 CHEMBL1909182 (2)
0 / 0
P08173 Muscarinic acetylcholine receptor M4 Acetylcholine receptor CHEMBL178 CHEMBL1909173 (2)
0 / 0
P25103 Substance-P receptor Neurokinin receptor CHEMBL178 CHEMBL1909113 (2)
0 / 0
P25105 Platelet-activating factor receptor PAF receptor CHEMBL178 CHEMBL1909187 (2)
0 / 0
P33032 Melanocortin receptor 5 Melanocortin receptor CHEMBL178 CHEMBL1909168 (2)
0 / 0
P33261 Cytochrome P450 2C19 Cytochrome P450 2C19 CHEMBL178 CHEMBL1525753 CHEMBL1741323 (2) CHEMBL1909134 (2)
1 / 1
P08684 Cytochrome P450 3A4 Cytochrome P450 3A4 CHEMBL178 CHEMBL1525753 CHEMBL1614108 (2) CHEMBL1613886 (2)
CHEMBL1741324 (2) CHEMBL1909138 (2)
0 / 1
P05181 Cytochrome P450 2E1 Cytochrome P450 2E1 CHEMBL178 CHEMBL1909137 (2)
0 / 0
P27695 DNA-(apurinic or apyrimidinic site) lyase Enzyme CHEMBL178 CHEMBL1525753 CHEMBL1614466 (1) CHEMBL1614211 (3)
0 / 0
P22309 UDP-glucuronosyltransferase 1-1 Enzyme CHEMBL178 CHEMBL1908080 (1)
5 / 1
P10636 Microtubule-associated protein tau Unclassified protein CHEMBL178 CHEMBL1614250 (2) CHEMBL1614421 (2)
4 / 3
P19224 UDP-glucuronosyltransferase 1-6 Enzyme CHEMBL178 CHEMBL1908083 (1)
0 / 0
P07477 Trypsin-1 S1A CHEMBL178 CHEMBL813733 (1)
1 / 1
P23975 Sodium-dependent noradrenaline transporter Norepinephrine CHEMBL178 CHEMBL1909094 (2)
1 / 1
P25100 Alpha-1D adrenergic receptor Adrenergic receptor CHEMBL178 CHEMBL1909087 (2)
0 / 0
P30542 Adenosine receptor A1 Adenosine receptor CHEMBL178 CHEMBL1909213 (2)
0 / 0
P18089 Alpha-2B adrenergic receptor Adrenergic receptor CHEMBL178 CHEMBL1909089 (2)
0 / 0
P24557 Thromboxane-A synthase Cytochrome P450 5A1 CHEMBL178 CHEMBL1909116 (2)
1 / 1
P06239 Tyrosine-protein kinase Lck Src CHEMBL178 CHEMBL1909206 (2)
0 / 1
P25025 C-X-C chemokine receptor type 2 CXC chemokine receptor CHEMBL178 CHEMBL1909128 (2)
0 / 0
Q9UBN7 Histone deacetylase 6 Hydrolase CHEMBL178 CHEMBL2025280 (1) CHEMBL2025747 (1)
CHEMBL2025748 (1)
0 / 0
O14746 Telomerase reverse transcriptase Enzyme CHEMBL178 CHEMBL808433 (1) CHEMBL808654 (1)
CHEMBL808655 (1)
5 / 5
Q9UBT6 DNA polymerase kappa Enzyme CHEMBL178 CHEMBL1525753 CHEMBL1794536 (3)
0 / 0
B2RXH2 Lysine-specific demethylase 4E Enzyme CHEMBL178 CHEMBL1613914 (1)
0 / 0
P46063 ATP-dependent DNA helicase Q1 Enzyme CHEMBL178 CHEMBL1525753 CHEMBL1613829 (3)
0 / 0
Q96KQ7 Histone-lysine N-methyltransferase EHMT2 Enzyme CHEMBL178 CHEMBL1525753 CHEMBL1738442 (2)
0 / 0
Q9NUW8 Tyrosyl-DNA phosphodiesterase 1 Enzyme CHEMBL178 CHEMBL1525753 CHEMBL1614364 (3)
1 / 1
O00255 Menin Unclassified protein CHEMBL178 CHEMBL1525753 CHEMBL1614257 (3) CHEMBL1614531 (3)
2 / 5
Q13951 Core-binding factor subunit beta Unclassified protein CHEMBL178 CHEMBL1613933 (1) CHEMBL1737904 (1)
CHEMBL1738444 (1)
0 / 1
Q01196 Runt-related transcription factor 1 Unclassified protein CHEMBL178 CHEMBL1613933 (1) CHEMBL1737904 (1)
CHEMBL1738444 (1)
1 / 6
O95255 Multidrug resistance-associated protein 6 Unclassified protein CHEMBL178 CHEMBL2077060 (1)
2 / 1
Q92769 Histone deacetylase 2 Hydrolase CHEMBL178 CHEMBL2025278 (1)
0 / 0

CTD interaction (250)

compound gene gene name gene description interaction interaction type form reference
pmid
D003630 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) ABCB1 affects the susceptibility to Daunorubicin affects response to substance
12174371
D003630 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) ABCB1 mutant form promotes the reaction [Daunorubicin results in decreased expression of ABCB1 mRNA] decreases expression
/ increases reaction
mRNA / mutant form 20957165
D003630 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) ABCB1 mutant form promotes the reaction [Daunorubicin results in decreased expression of ABCB1 protein] decreases expression
/ increases reaction
mutant form / protein 20957165
D003630 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) ABCB1 mutant form promotes the reaction [Magnetite Nanoparticles results in increased susceptibility to Daunorubicin] increases reaction
/ increases response to substance
mutant form 20957165
D003630 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) ABCB1 mutant form results in increased susceptibility to Daunorubicin increases response to substance
mutant form 20957165
D003630 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) ABCB1 protein results in decreased uptake of Daunorubicin decreases uptake
protein 10617675
D003630 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) ABCB1 protein results in increased export of Daunorubicin increases export
protein 12526924
D003630 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) ABCB1 protein results in increased transport of Daunorubicin increases transport
protein 11231118
12708479
D003630 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) Amiodarone inhibits the reaction [ABCB1 protein results in increased transport of Daunorubicin] decreases reaction
/ increases transport
protein 11231118
D003630 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) azelastine inhibits the reaction [ABCB1 protein results in increased transport of Daunorubicin] decreases reaction
/ increases transport
protein 11231118
D003630 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) carvedilol inhibits the reaction [ABCB1 protein results in increased transport of Daunorubicin] decreases reaction
/ increases transport
protein 12708479
D003630 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) [carvedilol inhibits the reaction [ABCB1 protein results in increased transport of Daunorubicin]] which results in decreased susceptibility to Daunorubicin decreases reaction
/ decreases response to substance
/ increases transport
protein 12708479
D003630 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) Cyclosporine inhibits the reaction [ABCB1 protein results in increased export of Daunorubicin] decreases reaction
/ increases export
protein 12526924
D003630 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) [Daunorubicin co-treated with bromotetrandrine co-treated with Magnetite Nanoparticles] results in decreased expression of ABCB1 mRNA affects cotreatment
/ decreases expression
mRNA 22114476
D003630 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) [Daunorubicin co-treated with bromotetrandrine] results in decreased expression of ABCB1 mRNA affects cotreatment
/ decreases expression
mRNA 22114476
D003630 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) Daunorubicin promotes the reaction [ABCB1 mutant form results in decreased expression of ABCB1 protein] decreases expression
/ increases reaction
mutant form / protein 20957165
D003630 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) Daunorubicin promotes the reaction [Magnetite Nanoparticles results in decreased expression of ABCB1 protein] decreases expression
/ increases reaction
protein 20957165
D003630 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) Daunorubicin results in decreased expression of ABCB1 mRNA decreases expression
mRNA 20957165
D003630 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) Daunorubicin results in decreased expression of ABCB1 protein decreases expression
protein 20957165
D003630 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) desethylamiodarone inhibits the reaction [ABCB1 protein results in increased transport of Daunorubicin] decreases reaction
/ increases transport
protein 11231118
D003630 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) desmethylazelastine inhibits the reaction [ABCB1 protein results in increased transport of Daunorubicin] decreases reaction
/ increases transport
protein 11231118
D003630 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) Magnetite Nanoparticles promotes the reaction [ABCB1 mutant form promotes the reaction [Daunorubicin results in decreased expression of ABCB1 mRNA]] decreases expression
/ increases reaction
mRNA / mutant form 20957165
D003630 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) Magnetite Nanoparticles promotes the reaction [ABCB1 mutant form promotes the reaction [Daunorubicin results in decreased expression of ABCB1 protein]] decreases expression
/ increases reaction
mutant form / protein 20957165
D003630 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) Magnetite Nanoparticles promotes the reaction [ABCB1 mutant form results in increased susceptibility to Daunorubicin] increases reaction
/ increases response to substance
mutant form 20957165
D003630 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) Magnetite Nanoparticles promotes the reaction [Daunorubicin promotes the reaction [ABCB1 mutant form results in decreased expression of ABCB1 protein]] decreases expression
/ increases reaction
mutant form / protein 20957165
D003630 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) Magnetite Nanoparticles promotes the reaction [Daunorubicin results in decreased expression of ABCB1 mRNA] decreases expression
/ increases reaction
mRNA 20957165
D003630 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) Magnetite Nanoparticles promotes the reaction [Daunorubicin results in decreased expression of ABCB1 protein] decreases expression
/ increases reaction
protein 20957165
D003630 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) Sesquiterpenes analog inhibits the reaction [ABCB1 protein results in decreased susceptibility to Daunorubicin] decreases reaction
/ decreases response to substance
protein 15466210
D003630 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) [Sodium Azide co-treated with Iodoacetates] inhibits the reaction [ABCB1 protein results in increased export of Daunorubicin] affects cotreatment
/ decreases reaction
/ increases export
protein 12526924
D003630 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) Verapamil inhibits the reaction [ABCB1 protein results in increased transport of Daunorubicin] decreases reaction
/ increases transport
protein 12708479
D003630 18671 ABCB1A protein results in increased export of Daunorubicin increases export
protein 16636798
D003630 18671 Cyclosporine inhibits the reaction [ABCB1A protein results in increased export of Daunorubicin] decreases reaction
/ increases export
protein 16636798
D003630 4363 ABCC1
ABC29
ABCC
GS-X
MRP
MRP1
ATP-binding cassette, sub-family C (CFTR/MRP), member 1 ABCC1 affects the susceptibility to Daunorubicin affects response to substance
12174371
18451141
D003630 4363 ABCC1
ABC29
ABCC
GS-X
MRP
MRP1
ATP-binding cassette, sub-family C (CFTR/MRP), member 1 ABCC1 protein affects the export of Daunorubicin affects export
protein 15498506
D003630 4363 ABCC1
ABC29
ABCC
GS-X
MRP
MRP1
ATP-binding cassette, sub-family C (CFTR/MRP), member 1 ABCC1 protein affects the susceptibility to Daunorubicin affects response to substance
protein 9096673
9334814
D003630 4363 ABCC1
ABC29
ABCC
GS-X
MRP
MRP1
ATP-binding cassette, sub-family C (CFTR/MRP), member 1 ABCC1 protein results in decreased susceptibility to Daunorubicin decreases response to substance
protein 12657726
D003630 4363 ABCC1
ABC29
ABCC
GS-X
MRP
MRP1
ATP-binding cassette, sub-family C (CFTR/MRP), member 1 ABCC1 protein results in increased secretion of Daunorubicin increases secretion
protein 12088114
15041471
D003630 4363 ABCC1
ABC29
ABCC
GS-X
MRP
MRP1
ATP-binding cassette, sub-family C (CFTR/MRP), member 1 ABCC1 results in decreased susceptibility to Daunorubicin decreases response to substance
12115804
D003630 4363 ABCC1
ABC29
ABCC
GS-X
MRP
MRP1
ATP-binding cassette, sub-family C (CFTR/MRP), member 1 Benzbromarone inhibits the reaction [ABCC1 protein results in increased secretion of Daunorubicin] decreases reaction
/ increases secretion
protein 15041471
D003630 4363 ABCC1
ABC29
ABCC
GS-X
MRP
MRP1
ATP-binding cassette, sub-family C (CFTR/MRP), member 1 Camptothecin inhibits the reaction [ABCC1 results in decreased susceptibility to Daunorubicin] decreases reaction
/ decreases response to substance
12115804
D003630 4363 ABCC1
ABC29
ABCC
GS-X
MRP
MRP1
ATP-binding cassette, sub-family C (CFTR/MRP), member 1 Folic Acid deficiency inhibits the reaction [ABCC1 protein results in increased secretion of Daunorubicin] decreases reaction
/ increases secretion
protein 15041471
D003630 4363 ABCC1
ABC29
ABCC
GS-X
MRP
MRP1
ATP-binding cassette, sub-family C (CFTR/MRP), member 1 homocamptothecin inhibits the reaction [ABCC1 protein results in increased secretion of Daunorubicin] decreases reaction
/ increases secretion
protein 12088114
D003630 4363 ABCC1
ABC29
ABCC
GS-X
MRP
MRP1
ATP-binding cassette, sub-family C (CFTR/MRP), member 1 PAK 104P inhibits the reaction [ABCC1 protein affects the export of Daunorubicin] affects export
/ decreases reaction
protein 15498506
D003630 4363 ABCC1
ABC29
ABCC
GS-X
MRP
MRP1
ATP-binding cassette, sub-family C (CFTR/MRP), member 1 Verapamil inhibits the reaction [ABCC1 protein affects the export of Daunorubicin] affects export
/ decreases reaction
protein 15498506
D003630 1244 ABCC2
ABC30
CMOAT
DJS
MRP2
cMRP
ATP-binding cassette, sub-family C (CFTR/MRP), member 2 ABCC2 affects the susceptibility to Daunorubicin affects response to substance
18451141
D003630 9429 ABCG2
ABC15
ABCP
BCRP
BCRP1
BMDP
CD338
CDw338
EST157481
GOUT1
MRX
MXR
MXR1
UAQTL1
ATP-binding cassette, sub-family G (WHITE), member 2 Dactinomycin inhibits the reaction [Daunorubicin results in increased expression of ABCG2 mRNA] decreases reaction
/ increases expression
mRNA 20019844
D003630 9429 ABCG2
ABC15
ABCP
BCRP
BCRP1
BMDP
CD338
CDw338
EST157481
GOUT1
MRX
MXR
MXR1
UAQTL1
ATP-binding cassette, sub-family G (WHITE), member 2 Daunorubicin results in increased expression of ABCG2 mRNA increases expression
mRNA 20019844
D003630 25 ABL1
ABL
JTK7
bcr/abl
c-ABL
p150
v-abl
c-abl oncogene 1, non-receptor tyrosine kinase (EC:2.7.10.2) ABL1 results in decreased susceptibility to Daunorubicin decreases response to substance
12410571
D003630 375790 AGRN
agrin Daunorubicin results in increased expression of AGRN mRNA increases expression
mRNA 17374387
D003630 10327 AKR1A1
ALDR1
ALR
ARM
DD3
aldo-keto reductase family 1, member A1 (aldehyde reductase) (EC:1.1.1.2) AKR1A1 protein results in increased reduction of Daunorubicin increases reduction
protein 18322072
D003630 10327 AKR1A1
ALDR1
ALR
ARM
DD3
aldo-keto reductase family 1, member A1 (aldehyde reductase) (EC:1.1.1.2) AKR1A1 results in increased metabolism of Daunorubicin increases metabolic processing
18276838
D003630 10327 AKR1A1
ALDR1
ALR
ARM
DD3
aldo-keto reductase family 1, member A1 (aldehyde reductase) (EC:1.1.1.2) [AKR1A1 results in increased metabolism of Daunorubicin] which results in increased chemical synthesis of daunorubicinol increases chemical synthesis
/ increases metabolic processing
18276838
D003630 10327 AKR1A1
ALDR1
ALR
ARM
DD3
aldo-keto reductase family 1, member A1 (aldehyde reductase) (EC:1.1.1.2) AKR1A1 SNP affects the metabolism of Daunorubicin affects metabolic processing
SNP 18276838
D003630 231 AKR1B1
ADR
ALDR1
ALR2
AR
aldo-keto reductase family 1, member B1 (aldose reductase) (EC:1.1.1.21) AKR1B1 protein results in increased reduction of Daunorubicin increases reduction
protein 10510318
D003630 57016 AKR1B10
AKR1B11
AKR1B12
ALDRLn
ARL-1
ARL1
HIS
HSI
aldo-keto reductase family 1, member B10 (aldose reductase) (EC:1.1.1.2) AKR1B10 protein results in decreased susceptibility to Daunorubicin decreases response to substance
protein 19028477
D003630 57016 AKR1B10
AKR1B11
AKR1B12
ALDRLn
ARL-1
ARL1
HIS
HSI
aldo-keto reductase family 1, member B10 (aldose reductase) (EC:1.1.1.2) AKR1B10 protein results in increased reduction of Daunorubicin increases reduction
protein 19028477
D003630 57016 AKR1B10
AKR1B11
AKR1B12
ALDRLn
ARL-1
ARL1
HIS
HSI
aldo-keto reductase family 1, member B10 (aldose reductase) (EC:1.1.1.2) [AKR1B10 protein results in increased reduction of Daunorubicin] which results in increased chemical synthesis of daunorubicinol increases chemical synthesis
/ increases reduction
protein 19028477
D003630 57016 AKR1B10
AKR1B11
AKR1B12
ALDRLn
ARL-1
ARL1
HIS
HSI
aldo-keto reductase family 1, member B10 (aldose reductase) (EC:1.1.1.2) ciprofibrate inhibits the reaction [AKR1B10 protein results in increased reduction of Daunorubicin] decreases reaction
/ increases reduction
protein 19028477
D003630 57016 AKR1B10
AKR1B11
AKR1B12
ALDRLn
ARL-1
ARL1
HIS
HSI
aldo-keto reductase family 1, member B10 (aldose reductase) (EC:1.1.1.2) ethyl 1-benzyl-3-hydroxy-2(5H)-oxopyrrole-4-carboxylate inhibits the reaction [AKR1B10 protein results in increased reduction of Daunorubicin] decreases reaction
/ increases reduction
protein 19028477
D003630 57016 AKR1B10
AKR1B11
AKR1B12
ALDRLn
ARL-1
ARL1
HIS
HSI
aldo-keto reductase family 1, member B10 (aldose reductase) (EC:1.1.1.2) Fenofibrate inhibits the reaction [AKR1B10 protein results in increased reduction of Daunorubicin] decreases reaction
/ increases reduction
protein 19028477
D003630 57016 AKR1B10
AKR1B11
AKR1B12
ALDRLn
ARL-1
ARL1
HIS
HSI
aldo-keto reductase family 1, member B10 (aldose reductase) (EC:1.1.1.2) fenofibric acid inhibits the reaction [AKR1B10 protein results in increased reduction of Daunorubicin] decreases reaction
/ increases reduction
protein 19028477
D003630 57016 AKR1B10
AKR1B11
AKR1B12
ALDRLn
ARL-1
ARL1
HIS
HSI
aldo-keto reductase family 1, member B10 (aldose reductase) (EC:1.1.1.2) pirinixic acid inhibits the reaction [AKR1B10 protein results in increased reduction of Daunorubicin] decreases reaction
/ increases reduction
protein 19028477
D003630 57016 AKR1B10
AKR1B11
AKR1B12
ALDRLn
ARL-1
ARL1
HIS
HSI
aldo-keto reductase family 1, member B10 (aldose reductase) (EC:1.1.1.2) sorbinil inhibits the reaction [AKR1B10 protein results in increased reduction of Daunorubicin] decreases reaction
/ increases reduction
protein 19028477
D003630 57016 AKR1B10
AKR1B11
AKR1B12
ALDRLn
ARL-1
ARL1
HIS
HSI
aldo-keto reductase family 1, member B10 (aldose reductase) (EC:1.1.1.2) zopolrestat inhibits the reaction [AKR1B10 protein results in increased reduction of Daunorubicin] decreases reaction
/ increases reduction
protein 19028477
D003630 8644 AKR1C3
DD3
DDX
HA1753
HAKRB
HAKRe
HSD17B5
PGFS
hluPGFS
aldo-keto reductase family 1, member C3 (EC:1.3.1.20 1.1.1.188 1.1.1.239 1.1.1.64 1.1.1.112 1.1.1.357) AKR1C3 results in increased metabolism of Daunorubicin increases metabolic processing
20837989
D003630 207 AKT1
AKT
CWS6
PKB
PKB-ALPHA
PRKBA
RAC
RAC-ALPHA
v-akt murine thymoma viral oncogene homolog 1 (EC:2.7.11.1) AKT1 protein results in decreased susceptibility to Daunorubicin decreases response to substance
protein 22252735
D003630 63982 ANO3
C11orf25
DYT23
DYT24
TMEM16C
anoctamin 3 ANO3 affects the susceptibility to Daunorubicin affects response to substance
17545624
D003630 302 ANXA2
ANX2
ANX2L4
CAL1H
LIP2
LPC2
LPC2D
P36
PAP-IV
annexin A2 Daunorubicin results in decreased expression of ANXA2 mRNA decreases expression
mRNA 21223737
D003630 302 ANXA2
ANX2
ANX2L4
CAL1H
LIP2
LPC2
LPC2D
P36
PAP-IV
annexin A2 Daunorubicin results in decreased expression of ANXA2 protein decreases expression
protein 21223737
D003630 307 ANXA4
ANX4
PIG28
ZAP36
annexin A4 Daunorubicin results in increased expression of ANXA4 mRNA increases expression
mRNA 17374387
D003630 328 APEX1
APE
APE1
APEN
APEX
APX
HAP1
REF1
APEX nuclease (multifunctional DNA repair enzyme) 1 (EC:4.2.99.18) APEX1 protein results in increased reduction of and results in increased susceptibility to Daunorubicin increases reduction
/ increases response to substance
protein 10190555
D003630 472 ATM
AT1
ATA
ATC
ATD
ATDC
ATE
TEL1
TELO1
ataxia telangiectasia mutated (EC:2.7.11.1) Daunorubicin results in increased expression of ATM mRNA increases expression
mRNA 12656675
D003630 580 BARD1
BRCA1 associated RING domain 1 Daunorubicin affects the expression of BARD1 mRNA affects expression
mRNA 12656675
D003630 581 BAX
BCL2L4
BCL2-associated X protein [bromotetrandrine co-treated with Daunorubicin] results in increased expression of BAX mRNA affects cotreatment
/ increases expression
mRNA 19421372
D003630 581 BAX
BCL2L4
BCL2-associated X protein [bromotetrandrine co-treated with Daunorubicin] results in increased expression of BAX protein affects cotreatment
/ increases expression
protein 19421372
D003630 581 BAX
BCL2L4
BCL2-associated X protein bromotetrandrine promotes the reaction [[ferric oxide co-treated with ferrous oxide co-treated with Daunorubicin] results in increased expression of BAX protein] affects cotreatment
/ increases expression
/ increases reaction
protein 19421372
D003630 581 BAX
BCL2L4
BCL2-associated X protein bromotetrandrine promotes the reaction [[Magnetite Nanoparticles co-treated with Daunorubicin] results in increased expression of BAX mRNA] affects cotreatment
/ increases expression
/ increases reaction
mRNA 19421372
D003630 581 BAX
BCL2L4
BCL2-associated X protein [Daunorubicin co-treated with bromotetrandrine co-treated with Magnetite Nanoparticles] results in increased expression of BAX mRNA affects cotreatment
/ increases expression
mRNA 21720514
D003630 581 BAX
BCL2L4
BCL2-associated X protein [Daunorubicin co-treated with bromotetrandrine co-treated with Magnetite Nanoparticles] results in increased expression of BAX protein affects cotreatment
/ increases expression
protein 21720514
D003630 581 BAX
BCL2L4
BCL2-associated X protein [Daunorubicin co-treated with bromotetrandrine] results in increased expression of BAX mRNA affects cotreatment
/ increases expression
mRNA 21720514
D003630 581 BAX
BCL2L4
BCL2-associated X protein [Daunorubicin co-treated with bromotetrandrine] results in increased expression of BAX protein affects cotreatment
/ increases expression
protein 21720514
D003630 581 BAX
BCL2L4
BCL2-associated X protein [Daunorubicin co-treated with Magnetite Nanoparticles] results in increased expression of BAX mRNA affects cotreatment
/ increases expression
mRNA 19918366
D003630 581 BAX
BCL2L4
BCL2-associated X protein [Magnetite Nanoparticles co-treated with Daunorubicin] promotes the reaction [bromotetrandrine results in increased expression of BAX protein] affects cotreatment
/ increases expression
/ increases reaction
protein 19421372
D003630 581 BAX
BCL2L4
BCL2-associated X protein [Magnetite Nanoparticles co-treated with Daunorubicin] results in increased expression of BAX mRNA affects cotreatment
/ increases expression
mRNA 19421372
D003630 581 BAX
BCL2L4
BCL2-associated X protein [Magnetite Nanoparticles co-treated with Daunorubicin] results in increased expression of BAX protein affects cotreatment
/ increases expression
protein 19421372
D003630 581 BAX
BCL2L4
BCL2-associated X protein Magnetite Nanoparticles promotes the reaction [[bromotetrandrine co-treated with Daunorubicin] results in increased expression of BAX mRNA] affects cotreatment
/ increases expression
/ increases reaction
mRNA 19421372
D003630 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 BCL2 results in decreased susceptibility to Daunorubicin decreases response to substance
21595920
D003630 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 [bortezomib co-treated with Daunorubicin] results in decreased expression of BCL2 mRNA affects cotreatment
/ decreases expression
mRNA 21302442
D003630 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 [bromotetrandrine co-treated with Daunorubicin] results in decreased expression of BCL2 protein affects cotreatment
/ decreases expression
protein 19421372
D003630 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 bromotetrandrine promotes the reaction [Daunorubicin results in decreased expression of BCL2 mRNA] decreases expression
/ increases reaction
mRNA 19421372
D003630 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 bromotetrandrine promotes the reaction [[Magnetite Nanoparticles co-treated with Daunorubicin] results in decreased expression of BCL2 protein] affects cotreatment
/ decreases expression
/ increases reaction
protein 19421372
D003630 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 bromotetrandrine promotes the reaction [Magnetite Nanoparticles promotes the reaction [Daunorubicin results in decreased expression of BCL2 mRNA]] decreases expression
/ increases reaction
mRNA 19421372
D003630 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 [Daunorubicin co-treated with bromotetrandrine co-treated with Magnetite Nanoparticles] results in decreased expression of BCL2 mRNA affects cotreatment
/ decreases expression
mRNA 21720514
D003630 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 [Daunorubicin co-treated with bromotetrandrine co-treated with Magnetite Nanoparticles] results in decreased expression of BCL2 protein affects cotreatment
/ decreases expression
protein 21720514
D003630 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 [Daunorubicin co-treated with bromotetrandrine] results in decreased expression of BCL2 mRNA affects cotreatment
/ decreases expression
mRNA 21720514
D003630 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 [Daunorubicin co-treated with bromotetrandrine] results in decreased expression of BCL2 protein affects cotreatment
/ decreases expression
protein 21720514
D003630 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 [Daunorubicin co-treated with Magnetite Nanoparticles] results in decreased expression of BCL2 mRNA affects cotreatment
/ decreases expression
mRNA 19918366
D003630 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 Daunorubicin results in decreased expression of BCL2 mRNA decreases expression
mRNA 19421372
D003630 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 [Magnetite Nanoparticles co-treated with Daunorubicin] promotes the reaction [bromotetrandrine results in decreased expression of BCL2 protein] affects cotreatment
/ decreases expression
/ increases reaction
protein 19421372
D003630 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 [Magnetite Nanoparticles co-treated with Daunorubicin] results in decreased expression of BCL2 protein affects cotreatment
/ decreases expression
protein 19421372
D003630 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 Magnetite Nanoparticles promotes the reaction [bromotetrandrine promotes the reaction [Daunorubicin results in decreased expression of BCL2 mRNA]] decreases expression
/ increases reaction
mRNA 19421372
D003630 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 Magnetite Nanoparticles promotes the reaction [Daunorubicin results in decreased expression of BCL2 mRNA] decreases expression
/ increases reaction
mRNA 19421372
D003630 637 BID
FP497
BH3 interacting domain death agonist [Daunorubicin co-treated with TNFSF10 protein] results in increased expression of BID protein affects cotreatment
/ increases expression
protein 12780785
D003630 332 BIRC5
API4
EPR-1
baculoviral IAP repeat containing 5 [bromotetrandrine co-treated with Daunorubicin] results in decreased expression of BIRC5 mRNA affects cotreatment
/ decreases expression
mRNA 21362215
D003630 332 BIRC5
API4
EPR-1
baculoviral IAP repeat containing 5 [bromotetrandrine co-treated with Daunorubicin] results in decreased expression of BIRC5 protein affects cotreatment
/ decreases expression
protein 21362215
D003630 332 BIRC5
API4
EPR-1
baculoviral IAP repeat containing 5 [Daunorubicin co-treated with bromotetrandrine co-treated with Magnetite Nanoparticles] results in decreased expression of BIRC5 mRNA affects cotreatment
/ decreases expression
mRNA 21720514
D003630 332 BIRC5
API4
EPR-1
baculoviral IAP repeat containing 5 [Daunorubicin co-treated with bromotetrandrine co-treated with Magnetite Nanoparticles] results in decreased expression of BIRC5 protein affects cotreatment
/ decreases expression
protein 21720514
D003630 332 BIRC5
API4
EPR-1
baculoviral IAP repeat containing 5 [Daunorubicin co-treated with bromotetrandrine] results in decreased expression of BIRC5 mRNA affects cotreatment
/ decreases expression
mRNA 21720514
D003630 332 BIRC5
API4
EPR-1
baculoviral IAP repeat containing 5 [Daunorubicin co-treated with bromotetrandrine] results in decreased expression of BIRC5 protein affects cotreatment
/ decreases expression
protein 21720514
D003630 152940 C4orf45
chromosome 4 open reading frame 45 C4ORF45 affects the susceptibility to Daunorubicin affects response to substance
17545624
D003630 51719 CAB39
MO25
calcium binding protein 39 Daunorubicin results in decreased expression of CAB39 mRNA decreases expression
mRNA 17374387
D003630 779 CACNA1S
CACNL1A3
CCHL1A3
Cav1.1
HOKPP
HOKPP1
MHS5
TTPP1
hypoPP
calcium channel, voltage-dependent, L type, alpha 1S subunit CACNA1S affects the susceptibility to Daunorubicin affects response to substance
17545624
D003630 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) [bromotetrandrine co-treated with Daunorubicin] results in increased expression of CASP3 mRNA affects cotreatment
/ increases expression
mRNA 19421372
D003630 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) [bromotetrandrine co-treated with Daunorubicin] results in increased expression of CASP3 protein affects cotreatment
/ increases expression
protein 19421372
D003630 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) bromotetrandrine promotes the reaction [[ferric oxide co-treated with ferrous oxide co-treated with Daunorubicin] results in increased expression of CASP3 protein] affects cotreatment
/ increases expression
/ increases reaction
protein 19421372
D003630 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) bromotetrandrine promotes the reaction [[Magnetite Nanoparticles co-treated with Daunorubicin] results in increased expression of CASP3 mRNA] affects cotreatment
/ increases expression
/ increases reaction
mRNA 19421372
D003630 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) [Daunorubicin co-treated with bromotetrandrine co-treated with Magnetite Nanoparticles] results in increased expression of CASP3 mRNA affects cotreatment
/ increases expression
mRNA 21720514
D003630 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) [Daunorubicin co-treated with bromotetrandrine co-treated with Magnetite Nanoparticles] results in increased expression of CASP3 protein affects cotreatment
/ increases expression
protein 21720514
D003630 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) [Daunorubicin co-treated with bromotetrandrine] results in increased expression of CASP3 mRNA affects cotreatment
/ increases expression
mRNA 21720514
D003630 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) [Daunorubicin co-treated with bromotetrandrine] results in increased expression of CASP3 protein affects cotreatment
/ increases expression
protein 21720514
D003630 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) [Daunorubicin co-treated with Magnetite Nanoparticles] results in increased expression of CASP3 mRNA affects cotreatment
/ increases expression
mRNA 19918366
D003630 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) [Daunorubicin co-treated with TNFSF10 protein] results in increased activity of CASP3 protein affects cotreatment
/ increases activity
protein 12780785
D003630 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) Daunorubicin results in increased activity of CASP3 protein increases activity
protein 10766178
17965967
19698806
D003630 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) [Magnetite Nanoparticles co-treated with Daunorubicin] promotes the reaction [bromotetrandrine results in increased expression of CASP3 protein] affects cotreatment
/ increases expression
/ increases reaction
protein 19421372
D003630 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) [Magnetite Nanoparticles co-treated with Daunorubicin] results in increased expression of CASP3 mRNA affects cotreatment
/ increases expression
mRNA 19421372
D003630 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) [Magnetite Nanoparticles co-treated with Daunorubicin] results in increased expression of CASP3 protein affects cotreatment
/ increases expression
protein 19421372
D003630 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) Magnetite Nanoparticles promotes the reaction [[bromotetrandrine co-treated with Daunorubicin] results in increased expression of CASP3 mRNA] affects cotreatment
/ increases expression
/ increases reaction
mRNA 19421372
D003630 841 CASP8
ALPS2B
CAP4
Casp-8
FLICE
MACH
MCH5
caspase 8, apoptosis-related cysteine peptidase (EC:3.4.22.61) [Daunorubicin co-treated with TNFSF10 protein] results in increased activity of CASP8 protein affects cotreatment
/ increases activity
protein 12780785
D003630 847 CAT
catalase (EC:1.11.1.6) CAT protein affects the susceptibility to Daunorubicin affects response to substance
protein 11178967
D003630 873 CBR1
CBR
SDR21C1
hCBR1
carbonyl reductase 1 (EC:1.1.1.189 1.1.1.197 1.1.1.184) CBR1 gene SNP results in decreased metabolism of Daunorubicin decreases metabolic processing
gene 19204081
D003630 873 CBR1
CBR
SDR21C1
hCBR1
carbonyl reductase 1 (EC:1.1.1.189 1.1.1.197 1.1.1.184) CBR1 protein results in increased reduction of Daunorubicin increases reduction
protein 18579125
D003630 873 CBR1
CBR
SDR21C1
hCBR1
carbonyl reductase 1 (EC:1.1.1.189 1.1.1.197 1.1.1.184) CBR1 results in increased metabolism of Daunorubicin increases metabolic processing
20670211
D003630 873 CBR1
CBR
SDR21C1
hCBR1
carbonyl reductase 1 (EC:1.1.1.189 1.1.1.197 1.1.1.184) [CBR1 results in increased metabolism of Daunorubicin] which results in increased chemical synthesis of daunorubicinol increases chemical synthesis
/ increases metabolic processing
20670211
D003630 874 CBR3
SDR21C2
hCBR3
carbonyl reductase 3 (EC:1.1.1.184) CBR3 gene SNP affects the susceptibility to Daunorubicin affects response to substance
gene 20007405
D003630 874 CBR3
SDR21C2
hCBR3
carbonyl reductase 3 (EC:1.1.1.184) CBR3 protein affects the metabolism of Daunorubicin affects metabolic processing
protein 20007405
D003630 874 CBR3
SDR21C2
hCBR3
carbonyl reductase 3 (EC:1.1.1.184) CBR3 protein alternative form affects the metabolism of Daunorubicin affects metabolic processing
protein 20007405
D003630 6347 CCL2
GDCF-2
HC11
HSMCR30
MCAF
MCP-1
MCP1
SCYA2
SMC-CF
chemokine (C-C motif) ligand 2 Daunorubicin results in decreased expression of CCL2 protein decreases expression
protein 20116850
D003630 6351 CCL4
ACT2
AT744.1
G-26
HC21
LAG-1
LAG1
MIP-1-beta
MIP1B
MIP1B1
SCYA2
SCYA4
chemokine (C-C motif) ligand 4 Daunorubicin results in decreased expression of CCL4 protein decreases expression
protein 20116850
D003630 896 CCND3
cyclin D3 Daunorubicin results in increased expression of CCND3 mRNA increases expression
mRNA 12656675
D003630 898 CCNE1
CCNE
cyclin E1 Daunorubicin affects the expression of CCNE1 mRNA affects expression
mRNA 12656675
D003630 901 CCNG2
cyclin G2 Daunorubicin results in increased expression of CCNG2 mRNA increases expression
mRNA 18754885
D003630 993 CDC25A
CDC25A2
cell division cycle 25A (EC:3.1.3.48) Daunorubicin results in increased expression of CDC25A mRNA increases expression
mRNA 12656675
D003630 1012 CDH13
CDHH
P105
cadherin 13 (EC:3.6.1.3) CDH13 affects the susceptibility to Daunorubicin affects response to substance
17545624
D003630 1026 CDKN1A
CAP20
CDKN1
CIP1
MDA-6
P21
SDI1
WAF1
p21CIP1
cyclin-dependent kinase inhibitor 1A (p21, Cip1) Daunorubicin results in increased expression of CDKN1A increases expression
12112851
D003630 1026 CDKN1A
CAP20
CDKN1
CIP1
MDA-6
P21
SDI1
WAF1
p21CIP1
cyclin-dependent kinase inhibitor 1A (p21, Cip1) Daunorubicin results in increased expression of CDKN1A mRNA increases expression
mRNA 12656675
D003630 1029 CDKN2A
ARF
CDK4I
CDKN2
CMM2
INK4
INK4A
MLM
MTS-1
MTS1
P14
P14ARF
P16
P16-INK4A
P16INK4
P16INK4A
P19
P19ARF
TP16
cyclin-dependent kinase inhibitor 2A Daunorubicin affects the expression of CDKN2A mRNA affects expression
mRNA 12656675
D003630 1030 CDKN2B
CDK4I
INK4B
MTS2
P15
TP15
p15INK4b
cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) Daunorubicin results in increased expression of CDKN2B mRNA increases expression
mRNA 12656675
D003630 634 CEACAM1
BGP
BGP1
BGPI
carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein) Daunorubicin results in increased expression of CEACAM1 mRNA increases expression
mRNA 17374387
D003630 10153 CEBPZ
CBF
CBF2
HSP-CBF
NOC1
CCAAT/enhancer binding protein (C/EBP), zeta Daunorubicin results in decreased expression of CEBPZ mRNA decreases expression
mRNA 17374387
D003630 1196 CLK2
hCLK2
CDC-like kinase 2 (EC:2.7.12.1) Daunorubicin results in increased expression of CLK2 mRNA increases expression
mRNA 12656675
D003630 171425 CLYBL
CLB
citrate lyase beta like CLYBL affects the susceptibility to Daunorubicin affects response to substance
17545624
D003630 56942 CMC2
2310061C15Rik
C16orf61
C-x(9)-C motif containing 2 CMC2 affects the susceptibility to Daunorubicin affects response to substance
17545624
D003630 80790 CMIP
TCMIP
c-Maf inducing protein CMIP affects the susceptibility to Daunorubicin affects response to substance
17545624
D003630 10283 CWC27
NY-CO-10
SDCCAG10
CWC27 spliceosome-associated protein homolog (S. cerevisiae) (EC:5.2.1.8) CWC27 affects the susceptibility to Daunorubicin affects response to substance
17545624
D003630 1545 CYP1B1
CP1B
CYPIB1
GLC3A
P4501B1
cytochrome P450, family 1, subfamily B, polypeptide 1 (EC:1.14.14.1) CYP1B1 affects the susceptibility to Daunorubicin affects response to substance
18451141
D003630 1676 DFFA
DFF-45
DFF1
ICAD
DNA fragmentation factor, 45kDa, alpha polypeptide Daunorubicin results in increased degradation of DFFA protein increases degradation
protein 12370496
D003630 1875 E2F5
E2F-5
E2F transcription factor 5, p130-binding Daunorubicin results in increased expression of E2F5 mRNA increases expression
mRNA 12656675
D003630 1950 EGF
HOMG4
URG
epidermal growth factor Daunorubicin inhibits the reaction [EGF protein results in increased abundance of Diglycerides] decreases reaction
/ increases abundance
protein 11082532
D003630 9538 EI24
EPG4
PIG8
TP53I8
etoposide induced 2.4 Daunorubicin results in increased expression of EI24 mRNA increases expression
mRNA 17374387
D003630 1978 EIF4EBP1
4E-BP1
4EBP1
BP-1
PHAS-I
eukaryotic translation initiation factor 4E binding protein 1 Daunorubicin results in increased phosphorylation of EIF4EBP1 protein increases phosphorylation
protein 21898527
D003630 1978 EIF4EBP1
4E-BP1
4EBP1
BP-1
PHAS-I
eukaryotic translation initiation factor 4E binding protein 1 Sirolimus inhibits the reaction [Daunorubicin results in increased phosphorylation of EIF4EBP1 protein] decreases reaction
/ increases phosphorylation
protein 21898527
D003630 9852 EPM2AIP1
EPM2A (laforin) interacting protein 1 Daunorubicin results in increased expression of EPM2AIP1 mRNA increases expression
mRNA 17374387
D003630 2232 FDXR
ADXR
ferredoxin reductase (EC:1.18.1.6) Daunorubicin results in increased expression of FDXR mRNA increases expression
mRNA 17374387
D003630 202309 GAPT
C5orf29
GRB2-binding adaptor protein, transmembrane GAPT affects the susceptibility to Daunorubicin affects response to substance
17545624
D003630 2262 GPC5
glypican 5 GPC5 affects the susceptibility to Daunorubicin affects response to substance
17545624
D003630 2944 GSTM1
GST1
GSTM1-1
GSTM1a-1a
GSTM1b-1b
GTH4
GTM1
H-B
MU
MU-1
glutathione S-transferase mu 1 (EC:2.5.1.18) GSTM1 gene polymorphism affects the susceptibility to Daunorubicin affects response to substance
gene 15713801
D003630 3184 HNRNPD
AUF1
AUF1A
HNRPD
P37
hnRNPD0
heterogeneous nuclear ribonucleoprotein D (AU-rich element RNA binding protein 1, 37kDa) HNRNPD affects the susceptibility to Daunorubicin affects response to substance
18451141
D003630 9641 IKBKE
IKK-E
IKK-i
IKKE
IKKI
inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase epsilon (EC:2.7.11.10) IKBKE affects the susceptibility to Daunorubicin affects response to substance
18451141
D003630 3570 IL6R
CD126
IL-6R-1
IL-6RA
IL6Q
IL6RA
IL6RQ
gp80
interleukin 6 receptor Daunorubicin results in decreased expression of IL6R protein modified form decreases expression
protein 20116850
D003630 3576 IL8
CXCL8
GCP-1
GCP1
LECT
LUCT
LYNAP
MDNCF
MONAP
NAF
NAP-1
NAP1
interleukin 8 Daunorubicin results in decreased expression of IL8 protein decreases expression
protein 20116850
D003630 80895 ILKAP
ILKAP2
ILKAP3
PP2C-DELTA
integrin-linked kinase-associated serine/threonine phosphatase (EC:3.1.3.16) ILKAP affects the susceptibility to Daunorubicin affects response to substance
17545624
D003630 8821 INPP4B
inositol polyphosphate-4-phosphatase, type II, 105kDa (EC:3.1.3.66) INPP4B affects the susceptibility to Daunorubicin affects response to substance
17545624
D003630 547 KIF1A
ATSV
C2orf20
HSN2C
MRD9
SPG30
UNC104
kinesin family member 1A KIF1A affects the susceptibility to Daunorubicin affects response to substance
17545624
D003630 4045 LSAMP
IGLON3
LAMP
limbic system-associated membrane protein LSAMP affects the susceptibility to Daunorubicin affects response to substance
17545624
D003630 338645 LUZP2
KFSP2566
PRO6246
leucine zipper protein 2 LUZP2 affects the susceptibility to Daunorubicin affects response to substance
17545624
D003630 4131 MAP1B
FUTSCH
MAP5
microtubule-associated protein 1B MAP1B affects the susceptibility to Daunorubicin affects response to substance
17545624
D003630 5606 MAP2K3
MAPKK3
MEK3
MKK3
PRKMK3
SAPKK-2
SAPKK2
mitogen-activated protein kinase kinase 3 (EC:2.7.12.2) Daunorubicin results in increased expression of MAP2K3 mRNA increases expression
mRNA 17374387
D003630 4217 MAP3K5
ASK1
MAPKKK5
MEKK5
mitogen-activated protein kinase kinase kinase 5 (EC:2.7.11.25) Daunorubicin results in decreased expression of MAP3K5 mRNA decreases expression
mRNA 17374387
D003630 4137 MAPT
DDPAC
FTDP-17
MAPTL
MSTD
MTBT1
MTBT2
PPND
TAU
microtubule-associated protein tau Daunorubicin results in decreased expression of MAPT mRNA decreases expression
mRNA 16930453
D003630 4137 MAPT
DDPAC
FTDP-17
MAPTL
MSTD
MTBT1
MTBT2
PPND
TAU
microtubule-associated protein tau Daunorubicin results in decreased expression of MAPT protein decreases expression
protein 16930453
D003630 4194 MDM4
HDMX
MDMX
MRP1
Mdm4 p53 binding protein homolog (mouse) Daunorubicin results in decreased expression of MDM4 mRNA decreases expression
mRNA 12656675
D003630 406991 MIR21
MIRN21
hsa-mir-21
miR-21
miRNA21
microRNA 21 MIR21 results in decreased susceptibility to Daunorubicin decreases response to substance
21187093
D003630 2475 MTOR
FRAP
FRAP1
FRAP2
RAFT1
RAPT1
mechanistic target of rapamycin (serine/threonine kinase) (EC:2.7.11.1) Daunorubicin results in increased phosphorylation of MTOR protein increases phosphorylation
protein 21898527
D003630 2475 MTOR
FRAP
FRAP1
FRAP2
RAFT1
RAPT1
mechanistic target of rapamycin (serine/threonine kinase) (EC:2.7.11.1) Sirolimus inhibits the reaction [Daunorubicin results in increased phosphorylation of MTOR protein] decreases reaction
/ increases phosphorylation
protein 21898527
D003630 8440 NCK2
GRB4
NCKbeta
NCK adaptor protein 2 Daunorubicin results in decreased expression of NCK2 mRNA decreases expression
mRNA 17374387
D003630 25791 NGEF
ARHGEF27
EPHEXIN
neuronal guanine nucleotide exchange factor NGEF affects the susceptibility to Daunorubicin affects response to substance
17545624
D003630 4864 NPC1
NPC
Niemann-Pick disease, type C1 Nocodazole inhibits the reaction [NPC1 protein results in increased secretion of Daunorubicin] decreases reaction
/ increases secretion
protein 16174794
D003630 4864 NPC1
NPC
Niemann-Pick disease, type C1 NPC1 affects the susceptibility to Daunorubicin affects response to substance
16174794
D003630 4864 NPC1
NPC
Niemann-Pick disease, type C1 NPC1 protein results in increased secretion of Daunorubicin increases secretion
protein 16174794
D003630 4864 NPC1
NPC
Niemann-Pick disease, type C1 Progesterone inhibits the reaction [NPC1 protein results in increased secretion of Daunorubicin] decreases reaction
/ increases secretion
protein 16174794
D003630 4879 NPPB
BNP
natriuretic peptide B Daunorubicin results in increased expression of NPPB protein increases expression
protein 11279304
D003630 1728 NQO1
DHQU
DIA4
DTD
NMOR1
NMORI
QR1
NAD(P)H dehydrogenase, quinone 1 (EC:1.6.5.2) Daunorubicin results in decreased expression of NQO1 mRNA decreases expression
mRNA 22021338
D003630 1728 NQO1
DHQU
DIA4
DTD
NMOR1
NMORI
QR1
NAD(P)H dehydrogenase, quinone 1 (EC:1.6.5.2) Daunorubicin results in decreased expression of NQO1 protein decreases expression
protein 22021338
D003630 2908 NR3C1
GCCR
GCR
GR
GRL
nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) Daunorubicin results in decreased activity of NR3C1 protein decreases activity
protein 19255438
D003630 4893 NRAS
ALPS4
N-ras
NRAS1
NS6
neuroblastoma RAS viral (v-ras) oncogene homolog Daunorubicin results in increased expression of NRAS mRNA increases expression
mRNA 12656675
D003630 142 PARP1
ADPRT
ADPRT_1
ADPRT1
ARTD1
PARP
PARP-1
PPOL
pADPRT-1
poly (ADP-ribose) polymerase 1 (EC:2.4.2.30) [Daunorubicin co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein affects cotreatment
/ increases cleavage
protein 12780785
D003630 142 PARP1
ADPRT
ADPRT_1
ADPRT1
ARTD1
PARP
PARP-1
PPOL
pADPRT-1
poly (ADP-ribose) polymerase 1 (EC:2.4.2.30) Daunorubicin results in increased cleavage of PARP1 protein increases cleavage
protein 10766178
11082532
D003630 5295 PIK3R1
AGM7
GRB1
p85
p85-ALPHA
phosphoinositide-3-kinase, regulatory subunit 1 (alpha) PIK3R1 affects the susceptibility to Daunorubicin affects response to substance
17545624
D003630 5327 PLAT
T-PA
TPA
plasminogen activator, tissue (EC:3.4.21.68) [Daunorubicin results in increased abundance of Ceramides] which results in increased secretion of PLAT protein increases abundance
/ increases secretion
protein 11107162
D003630 1263 PLK3
CNK
FNK
PRK
polo-like kinase 3 (EC:2.7.11.21) Daunorubicin results in increased expression of PLK3 mRNA increases expression
mRNA 17374387
D003630 10848 PPP1R13L
IASPP
NKIP1
RAI
RAI4
protein phosphatase 1, regulatory subunit 13 like PPP1R13L results in decreased susceptibility to Daunorubicin decreases response to substance
19299014
D003630 9055 PRC1
ASE1
protein regulator of cytokinesis 1 Daunorubicin results in decreased expression of PRC1 mRNA decreases expression
mRNA 17374387
D003630 5580 PRKCD
MAY1
PKCD
nPKC-delta
protein kinase C, delta (EC:2.7.10.2 2.7.11.13) Daunorubicin results in increased cleavage of PRKCD protein increases cleavage
protein 11082532
D003630 338095 PSME2P3 affects the susceptibility to Daunorubicin affects response to substance
17545624
D003630 5728 PTEN
10q23del
BZS
CWS1
DEC
GLM2
MHAM
MMAC1
PTEN1
TEP1
phosphatase and tensin homolog (EC:3.1.3.67 3.1.3.16 3.1.3.48) PTEN results in increased susceptibility to Daunorubicin increases response to substance
21187093
D003630 64901 RANBP17
RAN binding protein 17 RANBP17 affects the susceptibility to Daunorubicin affects response to substance
17545624
D003630 5925 RB1
OSRC
RB
p105-Rb
pRb
pp110
retinoblastoma 1 Daunorubicin results in increased expression of RB1 mRNA increases expression
mRNA 12656675
D003630 5929 RBBP5
RBQ3
SWD1
retinoblastoma binding protein 5 Daunorubicin affects the expression of RBBP5 mRNA affects expression
mRNA 12656675
D003630 5930 RBBP6
MY038
P2P-R
PACT
RBQ-1
SNAMA
retinoblastoma binding protein 6 Daunorubicin results in increased expression of RBBP6 mRNA increases expression
mRNA 12656675
D003630 5970 RELA
NFKB3
p65
v-rel avian reticuloendotheliosis viral oncogene homolog A [Daunorubicin co-treated with Magnetite Nanoparticles] results in decreased expression of RELA protein affects cotreatment
/ decreases expression
protein 21518493
D003630 6198 RPS6KB1
PS6K
S6K
S6K-beta-1
S6K1
STK14A
p70_S6KA
p70(S6K)-alpha
p70-S6K
p70-alpha
ribosomal protein S6 kinase, 70kDa, polypeptide 1 (EC:2.7.11.1) Daunorubicin results in increased phosphorylation of RPS6KB1 protein increases phosphorylation
protein 21898527
D003630 6198 RPS6KB1
PS6K
S6K
S6K-beta-1
S6K1
STK14A
p70_S6KA
p70(S6K)-alpha
p70-S6K
p70-alpha
ribosomal protein S6 kinase, 70kDa, polypeptide 1 (EC:2.7.11.1) Sirolimus inhibits the reaction [Daunorubicin results in increased phosphorylation of RPS6KB1 protein] decreases reaction
/ increases phosphorylation
protein 21898527
D003630 6382 SDC1
CD138
SDC
SYND1
syndecan
syndecan 1 Daunorubicin results in increased expression of SDC1 mRNA increases expression
mRNA 17374387
D003630 5054 SERPINE1
PAI
PAI-1
PAI1
PLANH1
serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 Daunorubicin results in decreased expression of SERPINE1 mRNA decreases expression
mRNA 11336794
D003630 5054 SERPINE1
PAI
PAI-1
PAI1
PLANH1
serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 Daunorubicin results in decreased expression of SERPINE1 protein decreases expression
protein 11336794
D003630 5054 SERPINE1
PAI
PAI-1
PAI1
PLANH1
serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 [Daunorubicin results in increased abundance of Ceramides] which results in decreased secretion of SERPINE1 protein decreases secretion
/ increases abundance
protein 11107162
D003630 5054 SERPINE1
PAI
PAI-1
PAI1
PLANH1
serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 fumonisin B1 inhibits the reaction [Daunorubicin results in decreased expression of SERPINE1 protein] decreases expression
/ decreases reaction
protein 11336794
D003630 42601 SKIP affects the susceptibility to Daunorubicin affects response to substance
17545624
D003630 85413 SLC22A16
CT2
FLIPT2
OAT6
OCT6
OKB1
dJ261K5.1
solute carrier family 22 (organic cation/carnitine transporter), member 16 Daunorubicin inhibits the reaction [SLC22A16 protein results in increased uptake of Doxorubicin] decreases reaction
/ increases uptake
protein 15963465
D003630 6586 SLIT3
MEGF5
SLIL2
SLIT1
Slit-3
slit2
slit homolog 3 (Drosophila) SLIT3 affects the susceptibility to Daunorubicin affects response to substance
17545624
D003630 6609 SMPD1
ASM
ASMASE
NPD
sphingomyelin phosphodiesterase 1, acid lysosomal (EC:3.1.4.12) Daunorubicin results in increased activity of SMPD1 protein increases activity
protein 19698806
D003630 6609 SMPD1
ASM
ASMASE
NPD
sphingomyelin phosphodiesterase 1, acid lysosomal (EC:3.1.4.12) Daunorubicin results in increased expression of SMPD1 mRNA increases expression
mRNA 19698806
D003630 55512 SMPD3
NSMASE2
sphingomyelin phosphodiesterase 3, neutral membrane (neutral sphingomyelinase II) (EC:3.1.4.12) Daunorubicin results in increased expression of SMPD3 mRNA increases expression
mRNA 19698806
D003630 55512 SMPD3
NSMASE2
sphingomyelin phosphodiesterase 3, neutral membrane (neutral sphingomyelinase II) (EC:3.1.4.12) Daunorubicin results in increased expression of SMPD3 protein increases expression
protein 19698806
D003630 55512 SMPD3
NSMASE2
sphingomyelin phosphodiesterase 3, neutral membrane (neutral sphingomyelinase II) (EC:3.1.4.12) SMPD3 results in increased susceptibility to Daunorubicin increases response to substance
19698806
D003630 3431 SP110
IFI41
IFI75
IPR1
VODI
SP110 nuclear body protein SP110 affects the susceptibility to Daunorubicin affects response to substance
17545624
D003630 6670 SP3
SPR2
Sp3 transcription factor Daunorubicin results in increased expression of SP3 protein increases expression
protein 19698806
D003630 29114 TAGLN3
NP22
NP24
NP25
transgelin 3 TAGLN3 affects the susceptibility to Daunorubicin affects response to substance
17545624
D003630 6890 TAP1
ABC17
ABCB2
APT1
D6S114E
PSF-1
PSF1
RING4
TAP1*0102N
TAP1N
transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) Daunorubicin results in increased expression of TAP1 mRNA increases expression
mRNA 17374387
D003630 6891 TAP2
ABC18
ABCB3
APT2
D6S217E
PSF-2
PSF2
RING11
transporter 2, ATP-binding cassette, sub-family B (MDR/TAP) TAP2 affects the susceptibility to Daunorubicin affects response to substance
18451141
D003630 30851 TAX1BP3
TIP-1
Tax1 (human T-cell leukemia virus type I) binding protein 3 Daunorubicin results in increased expression of TAX1BP3 mRNA increases expression
mRNA 17374387
D003630 79853 TM4SF20
PRO994
SLI5
TCCE518
transmembrane 4 L six family member 20 TM4SF20 affects the susceptibility to Daunorubicin affects response to substance
17545624
D003630 8797 TNFRSF10A
APO2
CD261
DR4
TRAILR-1
TRAILR1
tumor necrosis factor receptor superfamily, member 10a Daunorubicin promotes the reaction [TNFSF10 results in increased expression of TNFRSF10A mRNA] increases expression
/ increases reaction
mRNA 17204177
D003630 8795 TNFRSF10B
CD262
DR5
KILLER
KILLER/DR5
TRAIL-R2
TRAILR2
TRICK2
TRICK2A
TRICK2B
TRICKB
ZTNFR9
tumor necrosis factor receptor superfamily, member 10b Daunorubicin promotes the reaction [TNFSF10 results in increased expression of TNFRSF10B mRNA] increases expression
/ increases reaction
mRNA 17204177
D003630 8743 TNFSF10
APO2L
Apo-2L
CD253
TL2
TRAIL
tumor necrosis factor (ligand) superfamily, member 10 [Daunorubicin co-treated with TNFSF10 protein] results in increased activity of CASP3 protein affects cotreatment
/ increases activity
protein 12780785
D003630 8743 TNFSF10
APO2L
Apo-2L
CD253
TL2
TRAIL
tumor necrosis factor (ligand) superfamily, member 10 [Daunorubicin co-treated with TNFSF10 protein] results in increased activity of CASP8 protein affects cotreatment
/ increases activity
protein 12780785
D003630 8743 TNFSF10
APO2L
Apo-2L
CD253
TL2
TRAIL
tumor necrosis factor (ligand) superfamily, member 10 [Daunorubicin co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein affects cotreatment
/ increases cleavage
protein 12780785
D003630 8743 TNFSF10
APO2L
Apo-2L
CD253
TL2
TRAIL
tumor necrosis factor (ligand) superfamily, member 10 [Daunorubicin co-treated with TNFSF10 protein] results in increased expression of BID protein affects cotreatment
/ increases expression
protein 12780785
D003630 8743 TNFSF10
APO2L
Apo-2L
CD253
TL2
TRAIL
tumor necrosis factor (ligand) superfamily, member 10 Daunorubicin promotes the reaction [TNFSF10 results in increased expression of TNFRSF10A mRNA] increases expression
/ increases reaction
17204177
D003630 8743 TNFSF10
APO2L
Apo-2L
CD253
TL2
TRAIL
tumor necrosis factor (ligand) superfamily, member 10 Daunorubicin promotes the reaction [TNFSF10 results in increased expression of TNFRSF10B mRNA] increases expression
/ increases reaction
17204177
D003630 8744 TNFSF9
4-1BB-L
CD137L
tumor necrosis factor (ligand) superfamily, member 9 Daunorubicin results in increased expression of TNFSF9 mRNA increases expression
mRNA 17374387
D003630 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 [Daunorubicin co-treated with Magnetite Nanoparticles] results in increased activity of TP53 protein affects cotreatment
/ increases activity
protein 21518493
D003630 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 Daunorubicin results in increased activity of TP53 protein increases activity
protein 12112851
D003630 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 Daunorubicin results in increased expression of TP53 mRNA increases expression
mRNA 12656675
D003630 9540 TP53I3
PIG3
tumor protein p53 inducible protein 3 Daunorubicin results in increased expression of TP53I3 mRNA increases expression
mRNA 17374387
D003630 11257 TP53TG1
LINC00096
NCRNA00096
P53TG1
P53TG1-D
TP53AP1
TP53 target 1 (non-protein coding) Daunorubicin results in increased expression of TP53TG1 mRNA increases expression
mRNA 17374387
D003630 7298 TYMS
HST422
TMS
TS
thymidylate synthetase (EC:2.1.1.45) TYMS gene polymorphism affects the susceptibility to Daunorubicin affects response to substance
gene 15713801
D003630 7421 VDR
NR1I1
vitamin D (1,25- dihydroxyvitamin D3) receptor VDR gene polymorphism affects the susceptibility to Daunorubicin affects response to substance
gene 15713801
D003630 7422 VEGFA
MVCD1
VEGF
VPF
vascular endothelial growth factor A Daunorubicin results in decreased expression of VEGFA protein decreases expression
protein 20116850
D003630 26137 ZBTB20
DPZF
HOF
ODA-8S
ZNF288
zinc finger and BTB domain containing 20 ZBTB20 affects the susceptibility to Daunorubicin affects response to substance
17545624

Related Disease

Diseases related to proteins in ChEMBL interactions

OMIM (91)

OMIM preferred title UniProt
#300438 17-beta-hydroxysteroid dehydrogenase x deficiency Q99714
#100100 Abdominal muscles, absence of, with urinary tract abnormality and cryptorchidism P20309
#202300 Adrenocortical carcinoma, hereditary; adcc P04637
#103780 Alcohol dependence P08172
P14416
P31645
#614373 Amyotrophic lateral sclerosis 16, juvenile; als16 Q99720
#609135 Aplastic anemia O14746
#614473 Arterial calcification, generalized, of infancy, 2; gaci2 O95255
#614740 Basal cell carcinoma, susceptibility to, 7; bcc7 P04637
#601816 Bilirubin, serum level of, quantitative trait locus 1; biliqtl1 P22309
#614490 Blood group, junior system; jr Q9UNQ0
#210900 Bloom syndrome; blm P54132
#602025 Body mass index quantitative trait locus 9; bmiq9 P41968
#114480 Breast cancer P38398
#604370 Breast-ovarian cancer, familial, susceptibility to, 1; brovca1 P38398
#300615 Brunner syndrome P21397
#605479 Cholestasis, benign recurrent intrahepatic, 2; bric2 O95342
#601847 Cholestasis, progressive familial intrahepatic, 2; pfic2 O95342
#300882 Cornelia de lange syndrome 5; cdls5 Q9BY41
#218800 Crigler-najjar syndrome, type i P22309
#606785 Crigler-najjar syndrome, type ii P22309
#162800 Cyclic neutropenia P08246
#612522 Diabetes mellitus, insulin-dependent, 22; iddm22 P51681
#609535 Drug metabolism, poor, cyp2c19-related P33261
#608902 Drug metabolism, poor, cyp2d6-related P10635
#237500 Dubin-johnson syndrome; djs Q92887
#613989 Dyskeratosis congenita, autosomal dominant, 2; dkca2 O14746
#133239 Esophageal cancer P04637
#615363 Estrogen resistance; estrr P03372
#600274 Frontotemporal dementia; ftd P10636
#613659 Gastric cancer P04626
#137215 Gastric cancer, hereditary diffuse; hdgc P04626
#231095 Ghosal hematodiaphyseal dysplasia; ghdd P24557
#143500 Gilbert syndrome P22309
#137800 Glioma susceptibility 1; glm1 P04626
#605130 Hairy elbows, short stature, facial dysmorphism, and developmental delay Q03164
#609423 Human immunodeficiency virus type 1, susceptibility to P41597
P51681
#143100 Huntington disease; hd P42858
#237900 Hyperbilirubinemia, transient familial neonatal; hblrtfn P22309
#145000 Hyperparathyroidism 1; hrpt1 O00255
#612244 Inflammatory bowel disease 13; ibd13 P08183
#603932 Intervertebral disc disease; idd P14780
#151623 Li-fraumeni syndrome 1; lfs1 P04637
#613688 Long qt syndrome 2; lqt2 Q12809
#211980 Lung cancer P00533
P04626
P04637
#608516 Major depressive disorder; mdd P08172
#615134 Melanoma, cutaneous malignant, susceptibility to, 9; cmm9 O14746
#300705 Mental retardation, x-linked 17; mrx17 Q99714
%300852 Mental retardation, x-linked 88; mrx88 P50052
#300220 Mental retardation, x-linked, syndromic 10; mrxs10 Q99714
#613073 Metaphyseal anadysplasia 2; mandp2 P14780
#259600 Multicentric osteolysis, nodulosis, and arthropathy; mona P08253
#131100 Multiple endocrine neoplasia, type i; men1 O00255
#126200 Multiple sclerosis, susceptibility to; ms P08575
#607948 Mycobacterium tuberculosis, susceptibility to P11473
#159900 Myoclonic dystonia P14416
#202700 Neutropenia, severe congenital, 1, autosomal dominant; scn1 P08246
#601665 Obesity P32245
#164230 Obsessive-compulsive disorder; ocd P31645
#604715 Orthostatic intolerance P23975
#259730 Osteopetrosis, autosomal recessive 3; optb3 P00918
#167000 Ovarian cancer P04626
P38398
#614320 Pancreatic cancer, susceptibility to, 4; pnca4 P38398
#167800 Pancreatitis, hereditary; pctt P07477
#260500 Papilloma of choroid plexus; cpp P04637
#260540 Parkinson-dementia syndrome P10636
#613135 Parkinsonism-dystonia, infantile; pkdys Q01959
#172700 Pick disease of brain P10636
#601399 Platelet disorder, familial, with associated myeloid malignancy Q01196
#264800 Pseudoxanthoma elasticum; pxe O95255
#614742 Pulmonary fibrosis and/or bone marrow failure, telomere-related, 1; pfbmft1 O14746
#178500 Pulmonary fibrosis, idiopathic; ipf O14746
#607276 Resting heart rate, variation in P08588
#608971 Severe combined immunodeficiency, autosomal recessive, t cell-negative, b cell-positive, nk cell-positive P08575
#609620 Short qt syndrome 1; sqt1 Q12809
#253300 Spinal muscular atrophy, type i; sma1 Q16637
#253550 Spinal muscular atrophy, type ii; sma2 Q16637
#253400 Spinal muscular atrophy, type iii; sma3 Q16637
#271150 Spinal muscular atrophy, type iv; sma4 Q16637
#183090 Spinocerebellar ataxia 2; sca2 Q99700
#607250 Spinocerebellar ataxia, autosomal recessive, with axonal neuropathy; scan1 Q9NUW8
#275355 Squamous cell carcinoma, head and neck; hnscc P04637
#601104 Supranuclear palsy, progressive, 1; psnp1 P10636
#188570 Thyroid hormone resistance, generalized, autosomal dominant; grth P10828
#274300 Thyroid hormone resistance, generalized, autosomal recessive; grth P10828
#145650 Thyroid hormone resistance, selective pituitary; prth P10828
#190300 Tremor, hereditary essential, 1; etm1 P35462
#138900 Uric acid concentration, serum, quantitative trait locus 1; uaqtl1 Q9UNQ0
#277440 Vitamin d-dependent rickets, type 2a; vddr2a P11473
#610379 West nile virus, susceptibility to P51681
#309585 Wilson-turner x-linked mental retardation syndrome; wts Q9BY41
#112100 Yt blood group antigen P22303

KEGG DISEASE (85)

KEGG disease name UniProt
H00033 Adrenal carcinoma O00255 (related)
P04637 (related)
H00034 Carcinoid O00255 (related)
H00045 Malignant islet cell carcinoma O00255 (related)
H00246 Primary hyperparathyroidism O00255 (related)
H01102 Pituitary adenomas O00255 (related)
H00764 Cri du chat syndrome O14746 (related)
H01132 Aplastic anemia (AA) O14746 (related)
H01299 Idiopathic pulmonary fibrosis O14746 (related)
H00022 Bladder cancer O14746 (marker)
P00533 (related)
P04626 (related)
P04637 (related)
H00024 Prostate cancer O14746 (marker)
H00560 Pseudoxanthoma elasticum O95255 (related)
H00624 Familial cholestasis O95342 (related)
H00016 Oral cancer P00533 (related)
P00533 (marker)
P04637 (related)
P04637 (marker)
H00017 Esophageal cancer P00533 (related)
P04637 (related)
P04637 (marker)
P35354 (related)
H00018 Gastric cancer P00533 (related)
P04626 (related)
P04637 (related)
H00028 Choriocarcinoma P00533 (related)
P03956 (related)
P04626 (related)
P04637 (related)
P08253 (related)
H00030 Cervical cancer P00533 (related)
P04626 (related)
H00042 Glioma P00533 (related)
P00533 (marker)
P04637 (related)
P04637 (marker)
H00055 Laryngeal cancer P00533 (related)
P00533 (marker)
P04637 (related)
P04637 (marker)
H00241 Combined proximal and distal renal tubular acidosis (RTA type 3) P00918 (related)
H00436 Osteopetrosis P00918 (related)
H00026 Endometrial Cancer P03372 (marker)
P04626 (related)
P04637 (related)
Q92731 (marker)
H00599 46,XX disorders of sex development (Disorders related to androgen excess) P04150 (related)
H00019 Pancreatic cancer P04626 (related)
P04637 (related)
P04637 (marker)
H00027 Ovarian cancer P04626 (related)
P04637 (related)
P38398 (related)
H00031 Breast cancer P04626 (related)
P04626 (marker)
P04637 (related)
P38398 (related)
H00046 Cholangiocarcinoma P04626 (related)
P04637 (related)
P35354 (related)
H00004 Chronic myeloid leukemia (CML) P04637 (related)
Q01196 (related)
H00005 Chronic lymphocytic leukemia (CLL) P04637 (related)
H00006 Hairy-cell leukemia P04637 (related)
H00008 Burkitt lymphoma P04637 (related)
H00009 Adult T-cell leukemia P04637 (related)
H00010 Multiple myeloma P04637 (related)
H00013 Small cell lung cancer P04637 (related)
H00014 Non-small cell lung cancer P04637 (related)
H00015 Malignant pleural mesothelioma P04637 (related)
H00020 Colorectal cancer P04637 (related)
P04637 (marker)
H00025 Penile cancer P04637 (related)
P04637 (marker)
P08253 (related)
P14780 (related)
P35354 (related)
H00029 Vulvar cancer P04637 (related)
H00032 Thyroid cancer P04637 (related)
H00036 Osteosarcoma P04637 (related)
P08684 (marker)
H00038 Malignant melanoma P04637 (related)
H00039 Basal cell carcinoma P04637 (related)
H00040 Squamous cell carcinoma P04637 (related)
H00041 Kaposi's sarcoma P04637 (related)
H00044 Cancer of the anal canal P04637 (related)
H00047 Gallbladder cancer P04637 (related)
H00048 Hepatocellular carcinoma P04637 (related)
H00881 Li-Fraumeni syndrome P04637 (related)
H01007 Choroid plexus papilloma P04637 (related)
H00021 Renal cell carcinoma P04637 (marker)
H00093 Combined immunodeficiencies (CIDs) P06239 (related)
H00933 Hereditary pancreatitis P07477 (related)
H00079 Asthma P07550 (related)
H00100 Neutropenic disorders P08246 (related)
H00472 Torg-Winchester syndrome P08253 (related)
H00091 T-B+Severe combined immunodeficiencies (SCIDs) P08575 (related)
H00058 Amyotrophic lateral sclerosis (ALS) P10636 (related)
H00077 Progressive supranuclear palsy (PSP) P10636 (related)
H00078 Frontotemporal lobar degeneration (FTLD) P10636 (related)
H00249 Thyroid hormone resistance syndrome P10828 (related)
H00342 Tuberculosis P11473 (related)
H00784 Localized autosomal recessive hypotrichosis P11473 (related)
H01143 Vitamin D-dependent rickets P11473 (related)
H01205 Coumarin resistance P11712 (related)
H00479 Metaphyseal dysplasias P14780 (related)
H00548 Brunner syndrome P21397 (related)
H00208 Hyperbilirubinemia P22309 (related)
Q92887 (related)
H01031 Orthostatic intolerance (OI) P23975 (related)
H00490 Diaphyseal dysplasia with anemia (Ghosal) P24557 (related)
H01171 Poor drug metabolism (PM) P33261 (related)
H00059 Huntington's disease (HD) P42858 (related)
H00480 Non-syndromic X-linked mental retardation P50052 (related)
Q99714 (related)
H00094 DNA repair defects P54132 (related)
H00296 Defects in RecQ helicases P54132 (related)
H00001 Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia) Q01196 (related)
Q01196 (marker)
Q03164 (related)
Q03164 (marker)
H00003 Acute myeloid leukemia (AML) Q01196 (related)
Q01196 (marker)
Q13951 (marker)
H00978 Thrombocytopenia (THC) Q01196 (related)
H00002 Acute lymphoblastic leukemia (ALL) (precursor T lymphoblastic leukemia) Q03164 (related)
H00720 Long QT syndrome Q12809 (related)
H00725 Short QT syndrome Q12809 (related)
H00455 Spinal muscular atrophy (SMA) Q16637 (related)
Q16637 (related)
H00063 Spinocerebellar ataxia (SCA) Q99700 (related)
Q9NUW8 (related)
H00658 Syndromic X-linked mental retardation Q99714 (related)
H00925 2-Methyl-3-hydroxybutyryl-CoA dehydrogenase (MHBD) deficiency Q99714 (related)

Diseases related to CTD interactions

95 disease from interactions of metabolites

MeSH disease OMIM compound disease name evidence type reference
pmid
D000014 D003630 Abnormalities, Drug-Induced marker/mechanism
4259278
D000230 D003630 Adenocarcinoma marker/mechanism
639071
1268859
D000740 D003630 Anemia marker/mechanism
942366
7529655
D000741 D003630 Anemia, Aplastic marker/mechanism
12540035
D001145 D003630 Arrhythmias, Cardiac marker/mechanism
4990592
D001201 D003630 Ascites marker/mechanism
6648960
D001416 D003630 Back Pain marker/mechanism
10860143
12688316
D001847 D003630 Bone Diseases marker/mechanism
2250403
D001855 D003630 Bone Marrow Diseases marker/mechanism
16219352
17545624
D001929 D003630 Brain Edema therapeutic
2500219
D001932 D003630 Brain Neoplasms therapeutic
10100273
D002051 D003630 Burkitt Lymphoma therapeutic
3965085
D006528 D003630 Carcinoma, Hepatocellular therapeutic
21711951
D009202 D003630 Cardiomyopathies marker/mechanism
therapeutic
528374
713049
835599
1066982
1253124
1602607
2933147
3620638
6371643
6934026
7128476
8117986
8906433
9768820
10215105
10834529
10960060
11276319
11276320
11586415
16324756
16444662
17169121
17587482
17652820
20098333
D002471 D003630 Cell Transformation, Neoplastic marker/mechanism
1268859
D002493 D003630 Central Nervous System Diseases marker/mechanism
5293526
D002526 D003630 Cerebellar Diseases marker/mechanism
3684173
D002543 D003630 Cerebral Hemorrhage marker/mechanism
12531223
D002637 D003630 Chest Pain marker/mechanism
9849467
10860143
D002779 D003630 Cholestasis therapeutic
8895755
D003967 D003630 Diarrhea marker/mechanism
528374
3684173
D004195 D003630 Disease Models, Animal marker/mechanism
2250403
2352357
16324756
D004342 D003630 Drug Hypersensitivity marker/mechanism
5290866
D056486 D003630 Drug-Induced Liver Injury marker/mechanism
12204545
D064420 D003630 Drug-Related Side Effects and Adverse Reactions marker/mechanism
9758315
17545624
D004719 D003630 Endomyocardial Fibrosis marker/mechanism
1067858
D004890 D003630 Erythema marker/mechanism
11034047
D005334 D003630 Fever marker/mechanism
6155201
7529655
D018226 D003630 Fibroadenoma marker/mechanism
639071
1268859
D005355 D003630 Fibrosis marker/mechanism
20888384
D005921 D003630 Glomerulonephritis marker/mechanism
20037814
D005923 D003630 Glomerulosclerosis, Focal Segmental marker/mechanism
2408437
20037814
D006261 D003630 Headache marker/mechanism
1574039
D006331 D003630 Heart Diseases marker/mechanism
52088
94617
421236
1057758
2102164
2684736
4180386
4521474
4531839
5142139
6535952
6680300
6944597
8371139
11926284
12056608
12271153
16555089
17545624
20452391
20888384
21054405
D006333 D003630 Heart Failure marker/mechanism
180611
272983
291472
835599
983667
1253124
1266211
3481847
4338408
4519131
6934026
7049377
7359592
11279304
12540035
21046361
D006402 D003630 Hematologic Diseases marker/mechanism
6345018
15897593
D019337 D003630 Hematologic Neoplasms therapeutic
17545624
D006470 D003630 Hemorrhage marker/mechanism
20888384
D006504 D003630 Hepatic Veno-Occlusive Disease marker/mechanism
18839274
D006937 D003630 Hypercholesterolemia marker/mechanism
2072310
4029807
D006949 D003630 Hyperlipidemias marker/mechanism
6648960
D054559 D003630 Hyperphosphatemia marker/mechanism
2250403
D015228 D003630 Hypertriglyceridemia marker/mechanism
4029807
D007019 D003630 Hypoproteinemia marker/mechanism
8534155
D007022 D003630 Hypotension marker/mechanism
526912
9849467
D007235 D003630 Infant, Premature, Diseases marker/mechanism
7529655
D007239 D003630 Infection marker/mechanism
16219352
D007674 D003630 Kidney Diseases marker/mechanism
7055822
17922055
20452391
20888384
D007676 D003630 Kidney Failure, Chronic marker/mechanism
1895550
2250403
2352357
D007938 D003630 Leukemia marker/mechanism
therapeutic
5293526
17204177
D004915 D003630 Leukemia, Erythroblastic, Acute therapeutic
1357285
D007942 D003630 Leukemia, Experimental therapeutic
423182
D015470 D003630 Leukemia, Myeloid, Acute therapeutic
622432
1067858
1545569
1877195
1942537
2172608
3001234
3481411
3481847
3684173
3862678
4502569
4512951
4518764
6155201
6944597
7023715
7529655
8152248
9768826
10914541
12531223
12780785
16219352
20199376
20670211
20888384
D007952 D003630 Leukemia, Plasma Cell therapeutic
4571885
D015473 D003630 Leukemia, Promyelocytic, Acute therapeutic
1602607
7025685
7934481
8847803
9519692
10203107
11860447
18463343
20098333
20452391
D056784 D003630 Leukoencephalopathies therapeutic
15794179
D007970 D003630 Leukopenia marker/mechanism
7529655
D008107 D003630 Liver Diseases marker/mechanism
2352357
D017093 D003630 Liver Failure marker/mechanism
12531223
D008228 D003630 Lymphoma, Non-Hodgkin therapeutic
12688316
D015674 D003630 Mammary Neoplasms, Animal marker/mechanism
639071
1268859
2591446
D028361 D003630 Mitochondrial Diseases marker/mechanism
6929617
11391408
D052016 D003630 Mucositis marker/mechanism
16219352
D009205 D003630 Myocarditis marker/mechanism
180611
D009336 D003630 Necrosis marker/mechanism
1197900
12370496
20888384
D009369 D003630 Neoplasms therapeutic
11867198
12204545
D009401 D003630 Nephrosis marker/mechanism
873414
1895548
2072310
2263029
2408437
2444108
3599547
4029807
4130907
4454746
4654712
4654713
4717736
5431221
6648960
7302360
7637207
8450912
8501853
9849860
10591482
10592367
12030316
D009404 D003630 Nephrotic Syndrome marker/mechanism
2804744
7477632
8534155
9011594
D009422 D003630 Nervous System Diseases marker/mechanism
1574039
D009503 D003630 Neutropenia marker/mechanism
7529655
8305357
D010182 D003630 Pancreatic Diseases marker/mechanism
2352357
D010292 D003630 Paresthesia marker/mechanism
11034047
D010493 D003630 Pericarditis marker/mechanism
1066982
3047456
D010523 D003630 Peripheral Nervous System Diseases marker/mechanism
therapeutic
1545569
3001234
D011014 D003630 Pneumonia marker/mechanism
12531223
D015452 D003630 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma therapeutic
21064136
D054198 D003630 Precursor Cell Lymphoblastic Leukemia-Lymphoma therapeutic
180611
1574039
2265121
3152952
6345018
6944597
7808368
10881002
10910927
11193445
12116067
14561622
14984495
15794179
16479196
16696885
17179225
18839274
21297632
21898527
D054218 D003630 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma therapeutic
12426685
20167372
D011252 D003630 Pregnancy Complications, Neoplastic marker/mechanism
7529655
D011507 D003630 Proteinuria marker/mechanism
1895550
2072310
2352357
2408437
6648960
8534155
9011594
10592367
20037814
20888384
D012640 D003630 Seizures therapeutic
15794179
D012770 D003630 Shock, Cardiogenic marker/mechanism
3481411
D012804 D003630 Sick Sinus Syndrome marker/mechanism
1877195
D013280 D003630 Stomatitis marker/mechanism
16219352
D013616 D003630 Tachycardia, Sinus marker/mechanism
942366
D024801 D003630 Tauopathies therapeutic
16930453
D013921 D003630 Thrombocytopenia marker/mechanism
7529655
D013927 D003630 Thrombosis marker/mechanism
2933147
D013952 D003630 Thymus Hyperplasia marker/mechanism
11860447
D016171 D003630 Torsades de Pointes marker/mechanism
1942537
D014202 D003630 Tremor marker/mechanism
4518764
D014652 D003630 Vascular Diseases marker/mechanism
17179225
D018754 D003630 Ventricular Dysfunction marker/mechanism
3384249
3620638
8713574
D018487 D003630 Ventricular Dysfunction, Left marker/mechanism
6639100
8730759
10100273
14618274
18194856
D015431 D003630 Weight Loss marker/mechanism
12540035
15897593
20888384